Center for Security and Emerging Technology (CSET)’s Post

In the previous year, the White House issued an ambitious executive order aimed at promoting biotechnology and biomanufacturing. As part of this order, they pledged to invest $2B to stimulate development and production of biotech services and products. The goal of this investment is to boost both the economy and workforce of the US. Executive orders have historically been tools for driving change and growth within the US economy. A prime example of this is the New Deal, which was initiated by President Roosevelt's executive order in 1935. This order created numerous jobs and provided much needed relief to millions during the Great Depression. In this article Shelby N. and I dive into the potential impacts of the executive order on the future of R&D in biotech.

Ever imagined a future where biotechnology not only powers our industries but also safeguards our health and environment? Eric Schmidt, a pioneering figure in tech and biotech, lays out a compelling vision for the future in his latest article. From lab-grown meat to AI-driven disease prevention, the possibilities are vast and transformative. Schmidt shows how the biotech revolution, alongside AI, is set to reshape our economy and address global challenges like never before. But he also poses an urgent question: Is America ready to lead this revolution, or will it repeat past mistakes of losing ground in crucial high-tech sectors? This is a must-read for anyone interested in the intersection of technology, policy, and innovation. Explore how we can harness these breakthroughs responsibly and effectively. Don’t miss out on understanding the next big wave of change!

Testing the hypothesis vs. debating the hypothesis It seems like the size of an organization is inversely correlated with the reason why the organization exists. In drug discovery it would be the scientific progress, which in other words is hypothesis testing. The larger the organization the slower the hypothesis testing. This makes me think... Is growth a one way street and the company will inevitably lose it's agility and speed? Can company culture change this? Sounds like a hypothesis worth testing. Thanks Mark Tebbe for sharing why biotechs are moving fast and why rigorous science is essential. More on https://lnkd.in/eVFDW69d

Everyone occasionally likes to play the "I told you so" card, but in this case, like many others who I'm sure also saw this coming, I would have rather been wrong. The next big front for #USA 🇺🇸 vs #China 🇨🇳 competition is #biotech. This is about both #economics and #nationalsecurity. E/S: As our knowledge of biology grows and the cost comes down for 🧬 #DNA editing, syn-bio, and other #biotech products will compete with existing products "in sectors such as health and beauty, medical devices, and electronics will be challenged by syn-bio rivals—as the pharmaceutical and food industries already have been—in the next five years. Other industries, such as chemicals, textiles, fashion, and water." Much of the most advanced #researchanddevelopment in the field will come out of experiments, and potentially even drug manufacturing, in #space 🌌🌚 sparking incredible growth in the #spaceeconomy and providing anchor customers for 6-12 commercial space stations within the next decade. -GSP- MilkyWayEconomy

Think $12.2 billion is a big number? Well, that's the projected size of the whole genome synthesis market by 2030. With its rapid expansion comes a sea of opportunities and challenges. Here's something to chew on. According to the folks at Vantage Market Research, this market is on a rocket-like trajectory. Imagine the impact on life science firms, especially those with a focus on strategy, scaling, and enhanced capacity. The potential to be part of bringing life-saving technologies to market is enormous. Intrigued? Dive into the details here: https://lnkd.in/gBaeaEN7 Your move - Are you ready to be a part of this explosive growth? Let's chat about strategies on how to scale your organization.